A new test for cervical cancer was found to detect all of the cancers in a randomised clinical screening trial of 15,744 women, outperforming both the current Pap smear and human papillomavirus (HPV) test at a reduced cost, according to a study led by Queen Mary University of London.
The study, published in the International Journal of Cancer, compared a new ‘epigenetics-based’ cervical cancer test with Pap smear and HPV tests, and investigated how well it predicted the development of cervical cancer up to five years in advance in a large study of women aged 25-65 in Canada.
As opposed to checking for patterns in the DNA genetic code itself that are indicative of the HPV virus, the new test looks at the naturally-occurring chemical markers that appear on top of the DNA, making up its ‘epigenetic profile’.
‘An enormous development’
Lead researcher Professor Attila Lorincz from Queen Mary’s Wolfson Institute of Preventive Medicine who also helped develop the world’s first test for HPV in 1988, said: “This is an enormous development. We’re not only astounded by how well this test detects cervical cancer, but it is the first time that anyone has proven the key role of epigenetics in the development of a major solid cancer using data from patients in the clinic. Epigenetic changes are what this cervical cancer test picks up and is exactly why it works so well.
“In contrast to what most researchers and clinicians are saying, we are seeing more and more evidence that it is in fact epigenetics, and not DNA mutations, that drives a whole range of early cancers, including cervical, anal, oropharyngeal, colon, and prostate.”
Screening to prevent cervical cancer is typically done through the Pap smear, which involves the collection, staining and microscopic examination of cells from the cervix. Unfortunately, the Pap smear can detect only around 50 per cent of cervical pre-cancers.
A much more accurate cervical screening method involves testing for the presence of DNA from the human papillomavirus (HPV) – the primary but indirect cause of cervical cancer. There are estimated to be around 10 million women in the UK who are infected by HPV.
However, the HPV test only identifies whether or not women are infected with a cancer-causing HPV, but not their actual risks of cancer, which remain quite low. This causes unnecessary worry for the majority of HPV-infected women who receive a positive result but will eventually clear the virus and not develop the disease.
Predicting a person’s risk of cervical cancer
The new test was significantly better than either the Pap smear or HPV test. It detected 100 per cent of the eight invasive cervical cancers that developed in the 15,744 women during the trial. In comparison, the Pap smear only detected 25 per cent of the cancers, and the HPV test detected 50 per cent.
The study also looked more closely at a subset of 257 HPV-positive women which were representatively selected from the large study. The new test detected 93 per cent of pre-cancerous lesions in those women, compared to 86 per cent detected using a combination of the Pap smear and HPV test, and 61 per cent detected using the Pap smear on its own.
Reducing the number of screening appointments needed
Professor Lorincz added: “This really is a huge advance in how to deal with HPV-infected women and men, numbering in the billions worldwide, and it is going to revolutionise screening.
“We were surprised by how well this new test can detect and predict early cervical cancers years in advance, with 100 per cent of cancers detected, including adenocarcinomas, which is a type of cervical cancer that is very difficult to detect. The new test is much better than anything offered in the UK at present but could take at least five years to be established.”
The authors say that using this test in the clinic would reduce the number of visits to the doctor and screening appointments, as high-grade disease would be detected from the start. They also say that if it was fully implemented, it would be cheaper than the Pap smear.
The Latest on: Cervical cancer
via Google News
The Latest on: Cervical cancer
- With Multiple Late Stage Cancer Therapies, Agenus Inc. Offers The Best Risk/Reward Profile In Biotechnologyon July 9, 2020 at 11:22 am
FDA will fast track AGEN's PD-1 mono-therapy and CTLA-4/PD-1 combo-therapy BLA filings in 2nd line cervical cancer.
- Providing care for cervical cancer in Malawion July 9, 2020 at 9:37 am
In 2018, Ennerti became one of more than 3,600 Malawian women who fall sick with cervical cancer every year. Two-thirds of them end up dying from the disease, the most common type of cancer among ...
- Malawi: Providing Care for Cervical Cancer in Malawion July 9, 2020 at 8:59 am
Press Release - A diagnosis of cancer is a life-changing event. In Ennerti Williams' case, cervical cancer changed things in many ways: it affected not only her health, but also her ability to work ...
- GPs text messages boost cervical screening uptakeon July 9, 2020 at 7:50 am
In a study of almost 15,000 women in Northwest London, SMS reminders increased cervical screening participation by around five percent. Based on these findings, the NHS rolled out ...
- Cervical Cancer Diagnostic Market is Expected to Generate Huge Profits by 2020 - 2026 | Abbott Laboratories, Beckman Coulter, Becton, etc.on July 9, 2020 at 3:32 am
The Global Cervical Cancer Diagnostic Market is projected to grow at a considerable growth rate of 6.2% over the forecast period 2020-2026, as projected by the latest research report published by ...
- HPV Test Misses Twice as Many Women Who Develop Cervical Cancer as Cotesting, Quest Diagnostics Health Trends(TM) Study Findson July 8, 2020 at 4:36 am
PRNewswire/ -- A Health Trends(TM) study from researchers at Quest Diagnostics (NYSE: DGX) and the University of Pittsburgh Medical Center (UPMC) provides new evidence that ...
- HPV Test Misses Twice as Many Women Who Develop Cervical Cancer as Cotesting, Quest Diagnostics Health Trends™ Study Findson July 8, 2020 at 4:09 am
A Health Trends™ study from researchers at Quest Diagnostics (NYSE: DGX) and the University of Pittsburgh Medical Center (UPMC) provides new evidence that the HPV screening test is significantly less ...
- Combined PLT and NE to predict the prognosis of patients with locally advanced cervical canceron July 8, 2020 at 2:05 am
Cervical cancer is one of the most common tumors in women. Neutrophils (NEs) and platelets (PLTs) are components of cells in circulating blood. NEs are one of the components of white blood cells (WBCs ...
- The sponge with the secret recipe: A cancer-fighting chemicalon July 7, 2020 at 9:20 pm
Throughout the waters surrounding Indonesia, a porous tubular creature sits fixed onto coral reefs, its plain appearance hiding a potentially lifesaving secret. Researchers recently found that this ...
- Proposed study would test at-home screening for HPV and cervical canceron July 7, 2020 at 1:35 pm
With a tiny brush, briefly swab the vagina to collect cells. Then slide the swab into a screening kit and drop it into the mail.
via Bing News